{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:46:45Z","timestamp":1782460005986,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971166"],"award-info":[{"award-number":["31971166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12094-020-02478-5","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T14:02:54Z","timestamp":1598623374000},"page":"846-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Identification of a novel immune prognostic model in gastric cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4240-5378","authenticated-orcid":false,"given":"X.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"issue":"6","key":"2478_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"2478_CR2","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1016\/j.ejca.2012.07.029","volume":"48","author":"MP Lutz","year":"2012","unstructured":"Lutz MP, Zalcberg JR, Ducreux M, et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48(16):2941\u201353.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2478_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138.","journal-title":"Int J Cancer"},{"issue":"3","key":"2478_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","volume":"23","author":"LT Chen","year":"2020","unstructured":"Chen LT, Satoh T, Ryu MH, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2 year update data. Gastric Cancer. 2020;23(3):510\u20139.","journal-title":"Gastric Cancer"},{"issue":"5","key":"2478_CR5","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2478_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1039\/C9NR08086D","volume":"12","author":"S Han","year":"2020","unstructured":"Han S, Huang K, Gu Z, et al. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. Nanoscale. 2020;12(2):413\u201336.","journal-title":"Nanoscale"},{"issue":"1","key":"2478_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13046-019-1420-8","volume":"38","author":"C D'Alterio","year":"2019","unstructured":"D'Alterio C, Buoncervello M, Ieran\u00f2 C, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019;38(1):432.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2478_CR8","doi-asserted-by":"publisher","first-page":"e000326","DOI":"10.1136\/jitc-2019-000326","volume":"8","author":"LA Horn","year":"2020","unstructured":"Horn LA, Riskin J, Hempel HA, et al. Simultaneous inhibition of CXCR1\/2, TGF-\u03b2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. J Immunother Cancer. 2020;8(1):e000326.","journal-title":"J Immunother Cancer"},{"key":"2478_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ebiom.2019.03.022","volume":"42","author":"J Long","year":"2019","unstructured":"Long J, Wang A, Bai Y, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;42:363\u201374.","journal-title":"EBioMedicine"},{"issue":"1","key":"2478_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-020-02233-y","volume":"18","author":"X Shi","year":"2020","unstructured":"Shi X, Li R, Dong X, et al. IRGS: an immune-related gene classifier for lung adenocarcinoma prognosis. J Transl Med. 2020;18(1):55.","journal-title":"J Transl Med"},{"issue":"5","key":"2478_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"2478_CR12","doi-asserted-by":"publisher","first-page":"17036","DOI":"10.1038\/nrdp.2017.36","volume":"3","author":"JA Ajani","year":"2017","unstructured":"Ajani JA, Lee J, Sano T, et al. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.","journal-title":"Nat Rev Dis Primers"},{"key":"2478_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.critrevonc.2018.10.007","volume":"133","author":"C Coutzac","year":"2019","unstructured":"Coutzac C, Pernot S, Chaput N, et al. Immunotherapy in advanced gastric cancer, is it the future? Crit Rev Oncol Hematol. 2019;133:25\u2013322.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2478_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cellsig.2018.02.007","volume":"46","author":"CT Tang","year":"2018","unstructured":"Tang CT, Lin XL, Wu S, et al. NOX4-driven ROS formation regulates proliferation and apoptosis of gastric cancer cells through the GLI1 pathway. Cell Signal. 2018;46:52\u201363.","journal-title":"Cell Signal"},{"issue":"9","key":"2478_CR15","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","volume":"80","author":"K Ford","year":"2020","unstructured":"Ford K, Hanley CJ, Mellone M, et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020;80(9):1846\u201360.","journal-title":"Cancer Res"},{"issue":"5","key":"2478_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/cmi.2014.61","volume":"12","author":"W Wang","year":"2015","unstructured":"Wang W, Li T, Wang X, et al. FAM19A4 is a novel cytokine ligand of formyl peptide receptor 1 (FPR1) and is able to promote the migration and phagocytosis of macrophages. Cell Mol Immunol. 2015;12(5):615\u201324.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2478_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cam4.1364","volume":"7","author":"Y Yang","year":"2018","unstructured":"Yang Y, Shi Y, Hou Y, et al. CGB5 expression is independently associated with poor overall survival and recurrence-free survival in patients with advanced gastric cancer. Cancer Med. 2018;7(3):716\u201325.","journal-title":"Cancer Med"},{"issue":"1","key":"2478_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.12172","volume":"259","author":"J Barbi","year":"2014","unstructured":"Barbi J, Pardoll D, Pan F. Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014;259(1):115\u201339.","journal-title":"Immunol Rev"},{"issue":"6","key":"2478_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2478_CR20","doi-asserted-by":"publisher","first-page":"e3002","DOI":"10.1038\/cddis.2017.388","volume":"8","author":"FY Mao","year":"2017","unstructured":"Mao FY, Kong H, Zhao YL, et al. Increased tumor-infiltrating CD45RACCR7 regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress. Cell Death Dis. 2017;8(8):e3002.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2478_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-019-2131-y","volume":"10","author":"W Li","year":"2019","unstructured":"Li W, Zhang X, Wu F, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019;10(12):918.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2478_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s10120-015-0579-8","volume":"19","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Fushida S, Yamamoto Y, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2016;19(4):1052\u201365.","journal-title":"Gastric Cancer"},{"issue":"3","key":"2478_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2326-6066.CIR-16-0152","volume":"5","author":"LS Peng","year":"2017","unstructured":"Peng LS, Zhang JY, Teng YS, et al. Tumor-associated monocytes\/macrophages impair NK-cell function via TGF\u03b21 in human gastric cancer. Cancer Immunol Res. 2017;5(3):248\u201356.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2478_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, et al. CD4 T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635\u201347.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2478_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2478_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2478_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-018-1003-0","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Cong X, Gao H, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38(1):6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2478_CR28","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1038\/s41467-019-10676-1","volume":"10","author":"MF Eissmann","year":"2019","unstructured":"Eissmann MF, Dijkstra C, Jarnicki A, et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. Nat Commun. 2019;10(1):2735.","journal-title":"Nat Commun"},{"key":"2478_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","volume":"45","author":"E Kon","year":"2019","unstructured":"Kon E, Benhar I. Immune checkpoint inhibitor combinations: current efforts and important aspects for success. Drug Resist Updat. 2019;45:13\u201329.","journal-title":"Drug Resist Updat"},{"issue":"10111","key":"2478_CR30","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371.","journal-title":"Lancet"},{"issue":"4","key":"2478_CR31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s10120-018-00909-5","volume":"22","author":"YJ Bang","year":"2019","unstructured":"Bang YJ, Kang YK, Catenacci DV, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828\u201337.","journal-title":"Gastric Cancer"},{"issue":"10","key":"2478_CR32","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","volume":"71","author":"SF Ngiow","year":"2011","unstructured":"Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540\u201351.","journal-title":"Cancer Res"},{"issue":"10","key":"2478_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41416-020-0810-1","volume":"122","author":"H Ohmura","year":"2020","unstructured":"Ohmura H, Yamaguchi K, Hanamura F, et al. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer. 2020;122(10):1507\u201317.","journal-title":"Br J Cancer"},{"issue":"22","key":"2478_CR34","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","volume":"77","author":"W He","year":"2017","unstructured":"He W, Zhang H, Han F, et al. CD155T\/TIGIT Signaling regulates CD8 T-cell Metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 2017;77(22):6375\u201388.","journal-title":"Cancer Res"},{"issue":"4","key":"2478_CR35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/2326-6066.CIR-18-0637","volume":"7","author":"D Mittal","year":"2019","unstructured":"Mittal D, Lepletier A, Madore J, et al. CD96 Is an immune checkpoint that regulates CD8 T-cell antitumor function. Cancer Immunol Res. 2019;7(4):559\u201371.","journal-title":"Cancer Immunol Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02478-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T23:43:55Z","timestamp":1630107835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02478-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02478-5","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical stnadards."}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article did not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}